Found vs ShedRx (2026): prices, structure, verdict

On tirzepatide, the two are priced identically at $289 a month all-in — the decision moves entirely to structure.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, ShedRx↗ is cheaper: $249 versus $289 a month all-in — a $40 monthly gap, $480 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Found: the record, condensed

On tirzepatide, the number that matters at Found is $289 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.

To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

Start with the load-bearing figure: $289 a month, all-in, is what Found charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes Found unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

ShedRx: the record, condensed

ShedRx’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The structure is tiered: the advertised entry point is $199, but the maintenance figure — the one a full year is actually billed at — is $289. That $90 gap between the ad and the anniversary is the single most important line in this record.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #5 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

On semaglutide, the number that matters at ShedRx is $249 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The structure is tiered: the advertised entry point is $175, but the maintenance figure — the one a full year is actually billed at — is $249. That $74 gap between the ad and the anniversary is the single most important line in this record.

There is no membership line. $249 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 20 in the verified semaglutide index — $116/month above the floor (Oak Longevity, $133) — and sits $100 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,988.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Found at $289, ShedRx at $289 — a $0 monthly spread that compounds to $0 over a maintenance year and $0 over two. At identical prices, everything below — structure, transparency, terms — is the whole comparison.

Structure sharpens the gap: Found’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while ShedRx’s is not — so Found’s number is a ceiling and ShedRx’s advertised entry ($199) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $249 (ShedRx) against $289 (Found). $40 a month sounds survivable; $480 a year is a decision.

Structure sharpens the gap: Found’s figure is dose-flat (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill the same), while ShedRx’s is not — so Found’s number is a ceiling and ShedRx’s advertised entry ($175) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Run the same two programs on the committed basis: Found $289/mo month-to-month against ShedRx $289/mo month-to-month. The order holds: Found leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Found $867 monthly; ShedRx $867 monthly — best path favors Found by $0. 6 months: Found $1,734 monthly; ShedRx $1,734 monthly — best path favors Found by $0. 12 months: Found $3,468 monthly; ShedRx $3,468 monthly — best path favors Found by $0. 24 months: Found $6,936 monthly; ShedRx $6,936 monthly — best path favors Found by $0.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Found $867 vs ShedRx $747 — $120 to ShedRx. 6 mo: Found $1,734 vs ShedRx $1,494 — $240 to ShedRx. 12 mo: Found $3,468 vs ShedRx $2,988 — $480 to ShedRx. 24 mo: Found $6,936 vs ShedRx $5,976 — $960 to ShedRx.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Found publishes “most states”; ShedRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Found — none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front. ShedRx — none month-to-month; 72-hour notice before the next billing cycle.

Insurance: only Found does coverage work — decisive if there is any chance your plan covers a brand GLP-1, because a covered prescription beats both cash paths on this page.

Evidence: Found third-party reported (captured 2026-08-05); ShedRx source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #6 and #5 of 17: between them lie 0 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #15 and #13 of 20: between them lie 1 other program, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Found and ShedRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Found: membership recurs; prepaid terms are paid up front; ShedRx: 72-hour notice before the next billing cycle) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings